Skip to main content
Fig.1 | Journal of Translational Medicine

Fig.1

From: Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199

Fig.1

a qRT-PCR analysis of CPT1a mRNA expression (mean ± SEM)in normal cells (n = 8) and CN-AML samples (n = 325) (t-test). b Kaplan–Meier analysis of overall survival (OS) according to CPT1a mRNA expression in primary blasts from 325 AML patients. c Kaplan–Meier analysis of event free survival (EFS) according to CPT1a mRNA expression in primary blasts from 325 AML patients. d qPCR and Western blotting analysis of CPT1a expression in human AML cell lines. e Western blotting analysis of the CPT1a protein level in THP-1 and HL-60 cells transduced with 2 different CPT1a shRNAs. The NC shRNA was used as a knockdown control. f Cell viability at 0 h, 24 h, 48 h and 72 h in THP-1 and HL-60 cells transduced with 2 different CPT1a shRNAs

Back to article page